The clinical efficacy of Shenxiang Suhe Pill administration in posterior circulation ischemic vertigo: A randomized controlled trial

Author:

Zhang Yongjian1,Xu Lin2ORCID,Wang Xiaoping1,Ma Jianjun1,Song Xiaping1,Lv Heng2,Jin Luyao1

Affiliation:

1. Department of Cardiology, Haiyan Traditional Chinese Medicine Hospital, Haiyan, Zhejiang Province, China

2. Department of Cardiology, Zhejiang Tongde Hospital, Hangzhou, Zhejiang Province, China.

Abstract

Background: Shenxiang Suhe Pill (SXSHP) is a traditional Chinese medicine (TCM) widely used to treat coronary heart disease. The present study aims to investigate the effect of SXSHP on posterior circulation ischemic (PCI) vertigo. Methods: One hundred and twenty patients with PCI vertigo were randomly divided into the control, low-dose, and high-dose groups with 40 patients in each group. The control group was treated with basic Western medicine. The low-dose and high-dose groups were treated with 0.7 g SXSHP once a day in the morning and twice a day in the morning and evening, respectively. The assessments were performed on days 14 and 28. The traditional Chinese medicine symptom score, average blood flow velocity of vertebral artery and basilar artery, blood viscosity, blood lipids, serum C-reactive protein level (CRP), blood routine test, and liver and kidney function were compared before and after treatment among the 3 groups. Results: In the evaluation of the traditional Chinese medicine symptom score, both low-dose and high-dose SXSHP treatments showed higher efficacy than the control group (P = .013). The average blood flow velocity of vertebral artery and basilar artery in the 3 groups showed an upward trend from baseline (P < .05). The blood viscosity and levels of fibrinogen, hematocrit, and CRP in the 3 groups showed a downward trend from baseline level (P < .05). The levels of total cholesterol, triglycerides, low-density lipoprotein, and CRP in the low-dose group and high-dose group were lower than those in the control group on day 28 (P < .05). There were no significant differences in the routine blood test and liver and kidney function between the low-dose and high-dose groups compared with the baseline values (P > .05). Conclusion: SXSHP effectively improved PCI vertigo by inhibiting blood viscosity, regulating blood lipid levels, anti-inflammation, and improving cerebrovascular blood flow without affecting liver and kidney functions.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference15 articles.

1. Experimental study on the prevention and treatment of cardiovascular diseases by Shenxiang Suhe Pill.;Xiaoyu;J Zhejiang Univ Technol (Natural Science Edition),2016

2. Progress in imaging research of posterior circulation ischemic vertigo.;Peipei;Imaging Res Med Appl,2020

3. Posterior circulation ischaemic stroke.;Ng;Am J Med Sci,2022

4. Posterior circulation ischaemic stroke-a review part I: anatomy, aetiology and clinical presentations.;Sparaco;Neurol Sci,2019

5. Immune mechanisms of plaque instability.;Gerhardt;Front Cardiovasc Med,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3